UK's Mission divests kidney drug to Dimerix for $292m

pharmaphorum·5d ago

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Mission Therapeutics has divested a kidney drug, reportedly MTX652, to Dimerix in a deal worth up to $292 million. This move is said to be part of Mission Therapeutics' refocusing on central nervous system treatments. The exact terms and details of the deal are not entirely clear, but the transaction is valued at $292 million.

Full coverage

Mission Therapeutics refocuses on CNS and sells $292M kidney drug to Dimerix

European Biotechnology Magazine·5d ago

Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal

Manufacturing Chemist·2d ago

Mission Therapeutics divests MTX652 in deal worth up to $292m

Business Weekly·6d ago

Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer

Manufacturing Chemist·Apr 27

QIAGEN acquires Parse Biosciences Inc for US$225m

European Biotechnology Magazine·Nov 5

One in ten Britons are using or interested in using GLP-1s for weight loss, according to new research

Manufacturing Chemist·Jan 8

Roche acquires 89bio for US$3.5bn

European Biotechnology Magazine·Sep 18

Servier buys Day One for $2.5bn to bolster its rare cancer pipeline

European Biotechnology Magazine·Mar 9

View original report at pharmaphorum ↗

Fetching the latest headlines…